Publications by authors named "Mark B Effron"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

35

Total Likes

301

Extended Reach

825,023

Social Features

169
C
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
W Schuyler Jones, Hillary Mulder, Lisa M Wruck, Michael J Pencina, Sunil Kripalani, Daniel Muñoz, David L Crenshaw, Mark B Effron, Richard N Re, Kamal Gupta

N Engl J Med· May 2021

Videos about Article: user user

2 10 167 8 30

View All Article and Social Media Activity
P
Prognostic implications over time of platelet FcɣRIIa expression in patients with myocardial infarction: a secondary analysis.
David J Schneider, Sean R McMahon, Dominick J Angiolillo, Alexander C Fanaroff, Homam Ibrahim, Mark B Effron

J Invasive Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trial.
Dennis I Narcisse, Jeff Whittle, Grace M Rhodes, Amanda L Stebbins, Lisa M Wruck, Mark B Effron

Contemp Clin Trials· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of platelet FcγRIIa as a cardiovascular risk marker in patients in acute myocardial infarction.
Ahmad Hallak, Mark B Effron

Expert Rev Cardiovasc Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction.
David J Schneider, Sean R McMahon, Dominick J Angiolillo, Alexander C Fanaroff, Homam Ibrahim, Mark B Effron

Circ Cardiovasc Interv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry.
Ann Marie Navar, Nishant P Shah, Peter Shrader, Laine E Thomas, Zahid Ahmad, Mark B Effron

Am Heart J· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet FcγRIIa as a Marker of Cardiovascular Risk After Myocardial Infarction.
David J Schneider, Sean R McMahon, Dominick J Angiolillo, Alexander Fanaroff, Homam Ibrahim, Mark B Effron

J Am Coll Cardiol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Catherine P Benziger, Amanda Stebbins, Lisa M Wruck, Mark B Effron, Guillaume Marquis-Gravel

JAMA Cardiol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial.
Jennifer A Rymer, Hillary Mulder, Lisa M Wruck, Daniel Muñoz, Sunil Kripalani, Mark B Effron

JAMA Cardiol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial.
Guillaume Marquis-Gravel, Hillary Mulder, Lisa M Wruck, Catherine P Benziger, Mark B Effron

BMJ Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.
Guillaume Marquis-Gravel, Amanda Stebbins, Lisa M Wruck, Matthew T Roe, Mark B Effron

J Am Heart Assoc· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.
Eissa Jafari, Rhonda M Cooper-DeHoff, Mark B Effron, William R Hogan, Caitrin W McDonough

Am J Hypertens· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial.
Dennis I Narcisse, Hwasoon Kim, Lisa M Wruck, Amanda L Stebbins, Daniel Muñoz, Mark B Effron

Diabetes Care· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Amber Sleem, Mark B Effron, Amanda Stebbins, Lisa M Wruck, Guillaume Marquis-Gravel

JAMA Cardiol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More Potent Antiplatelet Therapy in Acute Coronary Syndrome Patients With Prior Stroke: Proceed With Caution?
Christopher M McKinnie, Mark B Effron

Mayo Clin Proc· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
Kamal Gupta, Harsh Mehta, Hwasoon Kim, Amanda Stebbins, Lisa M Wruck, Mark B Effron

Am Heart J· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Saket Girotra, Amanda Stebbins, Lisa Wruck, Guillaume Marquis-Gravel, Kamal Gupta, Mark B Effron

J Am Heart Assoc· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.
Mauro Chiarito, Davide Cao, Samantha Sartori, Zhongjie Zhang, Birgit Vogel, Mark B Effron

Eur Heart J Acute Cardiovasc Care· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial.
Connie N Hess, Judith Hsia, Ian A Carroll, Mark R Nehler, Wolfram Ruf, Mark B Effron

Arterioscler Thromb Vasc Biol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study.
Rebecca Shen, Hillary Mulder, Lisa Wruck, E Hope Weissler, Holly R Robertson, Mark B Effron

J Am Heart Assoc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.
Jacob Joseph, Nicholas M Pajewski, Rowena J Dolor, Mary Ann Sellers, Letitia H Perdue, Mark B Effron

J Am Geriatr Soc· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Predictors of Apparent Treatment Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.
Eissa Jafari, Rhonda M Cooper-DeHoff, Mark B Effron, William R Hogan, Caitrin W McDonough

medRxiv· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years.
John G Rizk, Aashish Gupta, Jose G Lazo, Partha Sardar, Brandon Michael Henry, Mark B Effron

Semin Thromb Hemost· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal for a Simple Algorithmic Approach to Manage Drug-Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients.
John G Rizk, Jose G Lazo, Aashish Gupta, Carl J Lavie, Mark B Effron

Semin Thromb Hemost· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial Disparities and Excess Cardiovascular Mortality Before and During the COVID-19 Pandemic: Time for a Solution.
Koyenum Obi, Mark B Effron

Mayo Clin Proc· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock.
Mark B Effron

Mayo Clin Proc· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis